Allen W. Burton, MD's portrait
Allen W. Burton, MD
Medical Director
Abbott Neuromodulation
Houston, TX

About Allen W. Burton, MD

Dr. Allen W. Burton is medical director of Abbott’s neuromodulation business, inclusive of Abbott’s neurostimulation and chronic pain management product portfolios. He is a board-certified anesthesiologist with an added certification in pain management and brings nearly 20 years of experience in patient care to Abbott, alongside a strong background leading large-scale clinical research programs.

Dr. Burton joined Abbott in October 2015 and served as principal investigator for the ACCURATE and SUNBURST clinical trials.

Prior to joining Abbott, he served as Chairman of the Department of Pain Medicine at the University of Texas MD Anderson Cancer Center from 2000-2011. From 2011-2015, Dr. Burton practiced privately with Houston Pain Associates, where he directed clinical research and participated in many clinical trials.

Dr. Burton obtained his bachelor of science at the University of Notre Dame, medical doctorate at Baylor College of Medicine, and completed his residency at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 50 peer-reviewed articles and authored two textbooks, taught and lectured nationally and internationally, and played an active leadership role among numerous pain societies and editorial boards.


Financial Disclosures

SpineUniverse, a Remedy Health Media, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.

To help achieve this goal, SpineUniverse requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.

The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.

This author has not yet submitted a Financial and Other Disclosures form.